Search Result

Results for "

KRAS(G12D) inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (3) PROTACs (1) Ras (32)
By Research Areas:	Cancer (34)
Click Chemistry:	Alkynes (10)

Inhibitors & Agonists

Peptides

Isotope-Labeled Compounds

Click Chemistry

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-144661

KRAS G12D inhibitor 14	Ras Apoptosis	Cancer
KRAS G12D inhibitor 14 is a potent *KRAS G12D* inhibitor with a K_D of 33 nM for binding to KRAS G12D protein. KRAS G12D inhibitor 14 decreases the active form of KRAS G12D (KRAS G12D-GTP) but not KRAS G13D .

HY-160445

KRAS G12D inhibitor 19

Others Cancer

KRAS G12D inhibitor 19 (Compound 7) is a KRAS G12D inhibitor. KRAS G12D inhibitor 19 can be used for the research of cancer .

KRAS G12D inhibitor 19	Others	Cancer
KRAS G12D inhibitor 19 (Compound 7) is a *KRAS G12D* inhibitor. KRAS G12D inhibitor 19 can be used for the research of cancer .

HY-148260

KRAS G12D inhibitor 16	Ras	Cancer
KRAS G12D inhibitor 16 is a *KRAS G12D* inhibitor. KRAS G12D inhibitor 16 has inhibitory activity against KRAS G12D and KRAS G12D mutation with IC₅₀ value of 0.7 nM and 0.35 μM, respectively. KRAS G12D inhibitor 16 can be used for the research of many malignant tumor, such as pancreatic ductal adenocarcinomas (PDAC), colon and rectal carcinomas (CRC), non-small cell lung carcinomas (NSCLC) .

HY-139894

KRAS G12D inhibitor 5

Ras Cancer

KRAS G12D inhibitor 5 is a KRAS G12D inhibitor for the potential research of pancreatic cancer.

KRAS G12D inhibitor 5	Ras	Cancer
KRAS G12D inhibitor 5 is a *KRAS G12D* inhibitor for the potential research of pancreatic cancer.

HY-115880

KRAS G12D inhibitor 3	Ras	Cancer
KRAS G12D inhibitor 3 is a *KRAS G12D* inhibitor with an IC₅₀ of <500 nM. KRAS G12D inhibitor 3 has antitumor effects (WO2022002102A1; compound 146) . KRAS G12D inhibitor 3 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-139911

KRAS G12D inhibitor 7

Ras Cancer

KRAS G12D inhibitor 7 is a potent inhibitor of KRAS G12D (extracted from patent WO2021108683, compound 114) .
HY-139910

KRAS G12D inhibitor 6

Ras Cancer

KRAS G12D inhibitor 6 is a potent inhibitor of KRAS G12D (extracted from patent WO2021108683A1, compound 112) .
HY-162366

KRAS G12D inhibitor 20

Ras Cancer

KRAS G12D inhibitor 20 (Compound 14) is a selective G12D KRAS inhibitor. KRAS G12D inhibitor 20 has antitumor activity .

KRAS G12D inhibitor 7	Ras	Cancer
KRAS G12D inhibitor 7 is a potent inhibitor of *KRAS G12D* (extracted from patent WO2021108683, compound 114) .

KRAS G12D inhibitor 6	Ras	Cancer
KRAS G12D inhibitor 6 is a potent inhibitor of *KRAS G12D* (extracted from patent WO2021108683A1, compound 112) .

KRAS G12D inhibitor 20	Ras	Cancer
KRAS G12D inhibitor 20 (Compound 14) is a selective G12D KRAS inhibitor. KRAS G12D inhibitor 20 has antitumor activity .

HY-147595

KRAS G12D inhibitor 15	Ras	Cancer
KRAS G12D inhibitor 15 is a potent inhibitor of *KRAS G12D. KRAS G12D* inhibitor 15 has the potential for the research of various diseases or disorders, such as cancer or cancer metastasis (extracted from patent WO2022042630A1, compound 243) . KRAS G12D inhibitor 15 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-115880A

KRAS G12D inhibitor 3 TFA	Ras	Cancer
KRAS G12D inhibitor 3 TFA is a *KRAS G12D* inhibitor with an IC₅₀ of <500 nM. KRAS G12D inhibitor 3 TFA has antitumor effects (WO2022002102A1; compound 146) . KRAS G12D inhibitor 3 (TFA) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-156819

RMC-9805 KRAS G12D inhibitor 18	Ras	Cancer
RMC-9805 (KRAS G12D inhibitor 18) is a *KRAS G12D* inhibitor . RMC-9805 is orally active. RMC-9805 inhibits RAS signaling and induces apoptosis in KRAS G12D mutant cancer cells .

HY-134811

KRAS G12D inhibitor 1	Ras	Cancer
KRAS G12D inhibitor 1 (example 243) is a *KRAS G12D* inhibitor, with an IC₅₀ of 0.8 nM for KRAS G12D-mediated ERK phosphorylation . KRAS G12D inhibitor 1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-143604

KRAS G12D inhibitor 11	Ras	Cancer
KRAS G12D inhibitor 11 is a potent inhibitor of *KRAS G12D. The Ras family of proteins is an important intracellular signaling molecule that plays an important role in growth and development. KRAS G12D* inhibitor 11 has the potential for the research of KRAS G12D-mediated cancer (extracted from patent WO2021108683A1, compound 52) .

HY-143606

KRAS G12D inhibitor 12	Ras	Cancer
KRAS G12D inhibitor 12 is a potent inhibitor of *KRAS G12D. The Ras family of proteins is an important intracellular signaling molecule that plays an important role in growth and development. KRAS G12D* inhibitor 12 has the potential for the research of KRAS G12D-mediated cancer (extracted from patent WO2021108683A1, compound 134) .

HY-143602

KRAS G12D inhibitor 9	Ras	Cancer
KRAS G12D inhibitor 9 is a potent inhibitor of *KRAS G12D. The Ras family of proteins is an important intracellular signaling molecule that plays an important role in growth and development. KRAS G12D* inhibitor 9 has the potential for the research of KRAS G12D-mediated cancer (extracted from patent WO2021108683A1, compound 20) .

HY-143603

KRAS G12D inhibitor 10	Ras	Cancer
KRAS G12D inhibitor 10 is a potent inhibitor of *KRAS G12D. The Ras family of proteins is an important intracellular signaling molecule that plays an important role in growth and development. KRAS G12D* inhibitor 10 has the potential for the research of KRAS G12D-mediated cancer (extracted from patent WO2021108683A1, compound 34) .

HY-143607

KRAS G12D inhibitor 13	Ras	Cancer
KRAS G12D inhibitor 13 is a potent inhibitor of *KRAS G12D. The Ras family of proteins is an important intracellular signaling molecule that plays an important role in growth and development. KRAS G12D* inhibitor 13 has the potential for the research of KRAS G12D-mediated cancer (extracted from patent WO2021108683A1, compound 142) .

HY-143599

KRAS G12D inhibitor 8	Ras	Cancer
KRAS G12D inhibitor 8 is a potent inhibitor of *KRAS G12D. The Ras family of proteins is an important intracellular signaling molecule that plays an important role in growth and development. KRAS G12D* inhibitor 8 has the potential for the research of KRAS G12D-mediated cancer (extracted from patent WO2021107160A1, compound 2) .

HY-148273

Setidegrasib KRAS G12D inhibitor 17	PROTACs Ras	Cancer
Setidegrasib (example 8) is a quinazoline-linked (4R)-4-hydroxy-L-prolinamide compound, inducing degradation of G12D-mutation KRAS protein. Setidegrasib is a PROTAC .

HY-153663

TH-Z827	Ras	Cancer
TH-Z827 is a mutant selective *KRAS(G12D)* inhibitor with an IC₅₀ of 2.4 μM. TH-Z827 does not bind KRAS(WT) or KRAS(G12C). TH-Z827 blocked the KRAS(G12D)-CRAF interaction with an IC₅₀ value of 42 μM .

HY-145962

MRTX-EX185	Ras	Cancer
MRTX-EX185 is a potent inhibitor of GDP-loaded KRAS and *KRAS(G12D), with an IC₅₀* of 90 nM for KRAS(G12D). MRTX-EX185 also binds GDP-loaded HRAS . MRTX-EX185 is a click chemistry reagent, itcontains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-145962A

MRTX-EX185 formic	Ras	Cancer
MRTX-EX185 formic is a potent inhibitor of GDP-loaded KRAS and *KRAS(G12D), with an IC₅₀* of 90 nM for KRAS(G12D). MRTX-EX185 formic also binds GDP-loaded HRAS . MRTX-EX185 (formic) is a click chemistry reagent, itcontains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-157029S

KRASG12D-IN-1	Ras	Cancer
KRASG12D-IN-1 (compound 22) is a KRAS ^G12D Inhibitor. KRASG12D-IN-1 has dose-dependent anti-tumor efficacy in the AsPC-1 xenograft mouse models with a tumor growth inhibition .

HY-157031S

KRASG12D-IN-2	Ras	Cancer
KRASG12D-IN-2 (compound 28) is a KRAS ^G12D Inhibitor. KRASG12D-IN-1 has dose-dependent anti-tumor efficacy in the AsPC-1 xenograft mouse models with a tumor growth inhibition .

HY-146243

TH-Z835	Ras Apoptosis	Cancer
TH-Z835 is a mutant selective *KRAS (G12D)* inhibitor with an IC₅₀ of 1.6 μM. TH-Z835 inhibits both mantGMPPNP/GPPNP exchange and GPPNP/mantGMPPNP exchange .

HY-134813

MRTX1133 3 Publications Verification	Ras	Cancer
MRTX1133 is a noncovalent, potent, and selective *KRAS G12D* inhibitor. MRTX1133 optimally fills the switch II pocket and extends three substituents to favorably interact with the protein, resulting in an estimated K_D against KRAS G12D of 0.2 pM. MRTX1133 prevents SOS1-catalyzed nucleotide exchange and/or formation of the KRAS G12D/GTP/RAF1 complex, thereby inhibiting mutant KRAS-dependent signal transduction. MRTX1133 selectively inhibits KRAS G12D mutant, but not KRAS wild-type, tumor cells. MRTX1133 has single digit nanomolar activity in cellular assays and marked in vivo efficacy in tumor models harboring KRAS G12D mutations .

HY-158007

(RS)-G12Di-1

Ras Cancer

(RS)-G12Di-1 is a selective, covalent inhibitor of K-Ras-G12D .

(RS)-G12Di-1	Ras	Cancer
(RS)-G12Di-1 is a selective, covalent inhibitor of *K-Ras-G12D* .

HY-162112

KRB-456	Ras	Cancer
KRB-456 is a small molecule that binds a dynamic allosteric binding pocket within the switch-I/II region of *KRAS G12D. KRB-456 inhibits* P-MEK, P-AKT, and P-S6 levels in vivo and inhibits the growth of cancer. KRB-456 can be used for the research of pancreatic cancer .

HY-122914

KRAS inhibitor-3	Ras	Cancer
KRAS inhibitor-3 is an inhibitor of KRAS inhibitor. KRAS inhibitor-3 binds to WT and oncogenic KRAS mutants with high affinity (K_D: 0.28 μM for KRAS WT, 0.63 μM for KRAS G12C, 0.37 μM for KRAS G12D, 0.74 μM for KRAS Q61H). KRAS inhibitor-3 also disrupts interaction of KRAS with Raf .

HY-137497

KRAS inhibitor-9	Ras Apoptosis	Cancer
KRAS inhibitor-9, a potent KRAS inhibitor (K_d=92 μM), blocks the formation of GTP-KRAS and downstream activation of KRAS. KRAS inhibitor-9 binds to KRAS G12D, KRAS G12C and KRAS Q61H protein with a moderate binding affinity. KRAS inhibitor-9 causes G2/M cell cycle arrest and induces apoptosis. KRAS inhibitor-9 selectively inhibits the proliferation of NSCLC cells with KRAS mutation but not normal lung cells .

HY-P2265

SAH-SOS1A	Ras	Cancer
SAH-SOS1A is a peptide-based SOS1/KRAS protein interaction inhibitor. SAH-SOS1A binds to wild-type and mutant KRAS (G12D, G12V, G12C, G12S, and Q61H) with nanomolar affinity (EC₅₀=106-175 nM), directly and independently blocks nucleotide association, impairs KRAS-driven cancer cell viability, and exerts its effects by on-mechanism blockade of the ERK-MAPK phosphosignaling cascade downstream of KRAS .

HY-126247

BI-2852	Ras	Cancer
BI-2852 is a KRAS inhibitor for the switch I/II pocket (SI/II-pocket) by structure-based agent design with nanomolar affinity. BI-2852 is mechanistically distinct from covalent KRASG12C inhibitor (binds to switch II pocket) and binds ten-fold more strongly to active KRASG12D versus KRASwt (740 nM vs 7.5 μM). BI-2852 blocks GEF, GAP, and effector interactions with KRAS, leading to inhibition of downstream signaling and an antiproliferative effect in KRAS mutant cells.

HY-P2265A

SAH-SOS1A TFA	Ras	Cancer
SAH-SOS1A TFA is a peptide-based SOS1/KRAS protein interaction inhibitor. SAH-SOS1A TFA binds to wild-type and mutant KRAS (G12D, G12V, G12C, G12S, and Q61H) with nanomolar affinity (EC₅₀=106-175 nM). SAH-SOS1A TFA directly and independently blocks nucleotide association. SAH-SOS1A TFA impairs KRAS-driven cancer cell viability and exerts its effects by on-mechanism blockade of the ERK-MAPK phosphosignaling cascade downstream of KRAS .

HY-126247B

(R)-BI-2852	Others	Cancer
(R)-BI-2852 is the isomer of BI-2852 (HY-126247), and can be used as an experimental control. BI-2852 is a KRAS inhibitor for the switch I/II pocket (SI/II-pocket) by structure-based agent design with nanomolar affinity. BI-2852 is mechanistically distinct from covalent KRASG12C inhibitor (binds to switch II pocket) and binds ten-fold more strongly to active KRASG12D versus KRASwt (740 nM vs 7.5 μM). BI-2852 blocks GEF, GAP, and effector interactions with KRAS, leading to inhibition of downstream signaling and an antiproliferative effect in KRAS mutant cells.

SAH-SOS1A TFA	Ras	Cancer
SAH-SOS1A TFA is a peptide-based SOS1/KRAS protein interaction inhibitor. SAH-SOS1A TFA binds to wild-type and mutant KRAS (G12D, G12V, G12C, G12S, and Q61H) with nanomolar affinity (EC₅₀=106-175 nM). SAH-SOS1A TFA directly and independently blocks nucleotide association. SAH-SOS1A TFA impairs KRAS-driven cancer cell viability and exerts its effects by on-mechanism blockade of the ERK-MAPK phosphosignaling cascade downstream of KRAS .

SAH-SOS1A	Ras	Cancer
SAH-SOS1A is a peptide-based SOS1/KRAS protein interaction inhibitor. SAH-SOS1A binds to wild-type and mutant KRAS (G12D, G12V, G12C, G12S, and Q61H) with nanomolar affinity (EC₅₀=106-175 nM), directly and independently blocks nucleotide association, impairs KRAS-driven cancer cell viability, and exerts its effects by on-mechanism blockade of the ERK-MAPK phosphosignaling cascade downstream of KRAS .

KRASG12D-IN-1
KRASG12D-IN-1 (compound 22) is a KRAS ^G12D Inhibitor. KRASG12D-IN-1 has dose-dependent anti-tumor efficacy in the AsPC-1 xenograft mouse models with a tumor growth inhibition .

KRASG12D-IN-2
KRASG12D-IN-2 (compound 28) is a KRAS ^G12D Inhibitor. KRASG12D-IN-1 has dose-dependent anti-tumor efficacy in the AsPC-1 xenograft mouse models with a tumor growth inhibition .

Cat. No.	Product Name		Classification

HY-134811

KRAS G12D inhibitor 1		Alkynes
KRAS G12D inhibitor 1 (example 243) is a *KRAS G12D* inhibitor, with an IC₅₀ of 0.8 nM for KRAS G12D-mediated ERK phosphorylation . KRAS G12D inhibitor 1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-115880

KRAS G12D inhibitor 3		Alkynes
KRAS G12D inhibitor 3 is a *KRAS G12D* inhibitor with an IC₅₀ of <500 nM. KRAS G12D inhibitor 3 has antitumor effects (WO2022002102A1; compound 146) . KRAS G12D inhibitor 3 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-147595

KRAS G12D inhibitor 15		Alkynes
KRAS G12D inhibitor 15 is a potent inhibitor of *KRAS G12D. KRAS G12D* inhibitor 15 has the potential for the research of various diseases or disorders, such as cancer or cancer metastasis (extracted from patent WO2022042630A1, compound 243) . KRAS G12D inhibitor 15 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-115880A

KRAS G12D inhibitor 3 TFA		Alkynes
KRAS G12D inhibitor 3 TFA is a *KRAS G12D* inhibitor with an IC₅₀ of <500 nM. KRAS G12D inhibitor 3 TFA has antitumor effects (WO2022002102A1; compound 146) . KRAS G12D inhibitor 3 (TFA) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-145962

MRTX-EX185		Alkynes
MRTX-EX185 is a potent inhibitor of GDP-loaded KRAS and *KRAS(G12D), with an IC₅₀* of 90 nM for KRAS(G12D). MRTX-EX185 also binds GDP-loaded HRAS . MRTX-EX185 is a click chemistry reagent, itcontains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-145962A

MRTX-EX185 formic		Alkynes
MRTX-EX185 formic is a potent inhibitor of GDP-loaded KRAS and *KRAS(G12D), with an IC₅₀* of 90 nM for KRAS(G12D). MRTX-EX185 formic also binds GDP-loaded HRAS . MRTX-EX185 (formic) is a click chemistry reagent, itcontains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-157029S

KRASG12D-IN-1		Alkynes
KRASG12D-IN-1 (compound 22) is a KRAS ^G12D Inhibitor. KRASG12D-IN-1 has dose-dependent anti-tumor efficacy in the AsPC-1 xenograft mouse models with a tumor growth inhibition .

HY-157031S

KRASG12D-IN-2		Alkynes
KRASG12D-IN-2 (compound 28) is a KRAS ^G12D Inhibitor. KRASG12D-IN-1 has dose-dependent anti-tumor efficacy in the AsPC-1 xenograft mouse models with a tumor growth inhibition .

HY-134813

MRTX1133 3 Publications Verification		Alkynes
MRTX1133 is a noncovalent, potent, and selective *KRAS G12D* inhibitor. MRTX1133 optimally fills the switch II pocket and extends three substituents to favorably interact with the protein, resulting in an estimated K_D against KRAS G12D of 0.2 pM. MRTX1133 prevents SOS1-catalyzed nucleotide exchange and/or formation of the KRAS G12D/GTP/RAF1 complex, thereby inhibiting mutant KRAS-dependent signal transduction. MRTX1133 selectively inhibits KRAS G12D mutant, but not KRAS wild-type, tumor cells. MRTX1133 has single digit nanomolar activity in cellular assays and marked in vivo efficacy in tumor models harboring KRAS G12D mutations .

HY-158007

(RS)-G12Di-1

Alkynes

(RS)-G12Di-1 is a selective, covalent inhibitor of K-Ras-G12D .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: